Cover Image
Market Research Report

Global Biosimilar's Market - 2018 - 2025

Published by DataM Intelligence Product code 757889
Published Content info 130-180 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Biosimilar's Market - 2018 - 2025
Published: October 1, 2018 Content info: 130-180 Pages
Description

The global biosimilar's market is estimated to be USD XX billion in 2017 and the market is estimated to grow at a double digit growth rate in the forecasted period 2018-2021.

Growing strategic partnerships among the companies for the development of the biosimilars, high growth of the biosimilars across the world, outsourcing of the biosimilars are some of the key trends observed in the global biosimilars market.

Market Dynamics

Low product development costs of the biosimilars (~200-300 million) compared to other biologics products (~700-800 million), less time taken for the products approval (~2-3 years less than biologics), growing demand for cost effective treatment, growing patent expiries, favourable reimbursements policies for the biosimilars, and strong product pipeline for the biosimilars are some of the major factors favouring the growth of the biosimilars. Limited availability of biosimilars, challenges in clinicals trials, and high risks of product failure are some of the key challenges in the biosimilars market.

Segmentation by Application

The Biosimilars market by application is segmented into oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and Autoimmune Disorders, and others. Oncology biosmiliars is one of the largest and the fastest growing market for biosimilars in the forecasted period. Large numbers of biosimilars are expected to lose its patent during the forecasted period while oncology biosimilars are estimated to launch during the same period strengthening the market for oncolytic biosimilars.

Segmentation by Geography

By geography, Europe dominated the global biosimilars market share in 2017. Regulatory support for the market and raising incidents for cancer in the European region are some of the major factors driving the European market. The market for biosimilars in the United Kingdom is mature, well established, and easy to enter making it one of the fastest growing regions in the European region. United States market is not favourable for the biosimilars due to poor access to biosimilars, and unconductive regulatory environment and because of which the market is growing at the slower rate but is estimated to grow in the forecasted period. Emerging nations have high presence of biosimilars and are highly supporting the growth of the market.

Scope of the Report

Segmentation by Therapy Type

Recombinant Non-Glycosylated Proteins

Human growth hormone

Granulocyte colony-stimulating factor

Interferons

Insulin

Recombinant Glycosylated Proteins

Erythropoietin

Monoclonal antibodies

Follitropin

Segmentation by Application

Oncology

Blood Disorders

Growth Hormonal Deficiency

Chronic and Autoimmune Disorders

Others

Segmentation by End User

Hospitals

Retail Pharmacies

The report also covers the key factors impacting the market, Porter 5 Forces, Market Share Analysis, Price trend analysis, Product Benchmarking, and company profiles.

Why Purchase the Report?

  • Visualize the composition of the global Biosimilars market with clear distinction between each design type and usage type.
  • Identify commercial opportunities in the global Biosimilars market analysing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global Biosimilars market.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1: Methodology and Scope

  • 1.1 Research Methodology
  • 1.2 Scope of the report

2: Industry Analysis

  • 2.1 Market Drivers
  • 2.2 Market Restraints
  • 2.3 Porters Five Forces

3. Market Overview

  • 3.1 Epidemiology Analysis
  • 3.2 Clinical Trial Analysis

4. Product Pipeline Analysis

5. Segmentation by Therapy Type

  • 5.1 Recombinant Non-Glycosylated Proteins
    • 5.1.1 Human growth hormone
    • 5.1.2 Granulocyte colony-stimulating factor
    • 5.1.3 Interferons
    • 5.1.4 Insulin
  • 5.2 Recombinant Glycosylated Proteins
    • 5.2.1 Erythropoietin
    • 5.2.2 Monoclonal antibodies
    • 5.2.3 Follitropin

6. Segmentation by Application

  • 6.1 Oncology
  • 6.2 Blood Disorders
  • 6.3 Growth Hormonal Deficiency
  • 6.4 Chronic and Autoimmune Disorders
  • 6.5 Others

7. Segmentation by End User

  • 7.1 Hospitals
  • 7.2 Retail Pharmacies

8. Segmentation by Geography

  • 8.1 North America
    • 8.1.1 United States
    • 8.1.2 Canada
    • 8.1.3 Mexico
    • 8.1.4 Rest of North America
  • 8.2 Europe
    • 8.2.1 United Kingdom
    • 8.2.2 Germany
    • 8.2.3 Spain
    • 8.2.4 France
    • 8.2.5 Rest of Europe
  • 8.3 Asia-Pacific
    • 8.3.1 China
    • 8.3.2 Japan
    • 8.3.3 India
    • 8.3.4 Australia
    • 8.3.5 Rest of Asia-Pacific
  • 8.4 South America
    • 8.4.1 Brazil
    • 8.4.2 Argentina
    • 8.4.3 Rest of South America
  • 8.5 Rest of the World

9. Competitive Landscape

  • 9.1 Market Player Analysis
  • 9.2 Key Strategies Adopted by Major companies

10. Company Profiles

  • 10.1 Sandoz
  • 10.2 Hospira
  • 10.3 Teva Pharmaceuticals
  • 10.4 STADA
  • 10.5 Biocon
  • 10.6 Cellitron
  • 10.7 Dr. Reddy's
  • 10.8 Pfizer
  • 10.9 Mylan
  • 10.10 AbbVie Inc

11. Appendix

  • 11.1 Disclaimer
  • 11.2 Contact Us
Back to Top